Company Profile
|
Purple Biotech Ltd.
(NASDAQ: PPBT)
|
9:00 PM UTC, 01/08/25 | |||
|---|---|---|---|---|
| Last: $3.78 | Change: -0.41 | %Change: -9.79% | Volume: 53,010 | |
Detailed Quote
M = Million B = Billion
Price Performance
Management Effectiveness
Profitability
| Open: | $ 4.04 | Volume: | 53,010 | |
|---|---|---|---|---|
| High: | $ 4.13 | Yield(%) | 0.00 | |
| Low: | $ 3.78 | P/E Ratio (ttm): | n/a | |
| Dividend ($): | n/a | Market Cap ($): | 9.77M | |
| EPS ($) | -8.94 | Shares Out: | 2.59M |
| % Price Change (last 4 weeks): | -5.97 |
|---|---|
| % Price Change (last 13 weeks): | -9.35 |
| % Price Change (last 26 weeks): | -54.22 |
| % Price Change (last 52 weeks): | -71.57 |
| % Price Change (year to date): | -19.40 |
| Return on Equity (%): | -49.02 |
|---|---|
| Return on Assets (%): | -40.19 |
| Return on Invested Capital (%): | -43.37 |
| Gross Profit Margin (%): | n/a |
|---|---|
| Net Profit Margin (%): | n/a |
| Operating Profit Margin (%): | 0.00 |
Price & Volume
Company Information
Per Share Data
Valuation Ratios
Financial Strength
|
|
|
| 50-day Moving Average: | $n/a |
|---|---|
| 200-day Moving Average: | $n/a |
| Avg. Daily Vol. (last 50 days): | n/a |
| Avg. Daily Vol. (last 200 days): | n/a |
| 52-wk high: | $20.60 |
| 52-wk low: | $2.00 |
| Bid: | $3.78 |
| Ask: | $4.00 |
|
Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. It operates through two segments: Oncology, and Pain & Hypertension. The Oncology segment includes NT219, a therapeutic candidate which is a small molecule that targets two signal transduction pathways which are involved in the development of cancer drug resistance mechanisms, and which is currently in the late pre-clinical stage of development. The Pain & Hypertension segment includes Consensi, a combination drug for the simultaneous treatment of two clinical conditions, pain caused by osteoarthritis and hypertension (high blood pressure), which can be pre-existing or caused by the treatment for osteoarthritis. The company was founded by John Paul Waymack on August 12, 1968 and is headquartered in Rehovot, Israel.
|
|
Purple Biotech Ltd.
Science Park 4 Oppenheimer Street Rehovot TA 7670104 Phone: 972.3.933.3121 Fax: n/a http://www.purple-biotech.com |
| Earnings (1year) ($): | -8.94 |
|---|---|
| Annual Dividend ($): | 0.00 |
| Current P/E Ratio (ttm): | n/a |
| Book Value ($): | 27.11 |
| Cash Flow ($): | -15.99 |
| Price/Earnings (x): | n/a |
|---|---|
| Price/Sales (x): | n/a |
| Price/Book (x): | 0.58 |
| Price/Cash Flow (x): | n/a |
| Quick Ratio (x): | 2.20 |
|---|---|
| Current Ratio (x): | 2.20 |
| LT Debt/Equity (x): | 0.48 |
| Total Debt/Equity (x): | 1.03 |
